Spexis to present at BioEquity Europe 2022

Spexis AG / Key word(s): Conference
Spexis to present at BioEquity Europe 2022
12.05.2022 / 07:30 CET

Allschwil, Switzerland, May 12, 2022

Spexis AG (SIX: SPEX) today announced that that the company will present at BioEquity Europe, taking place May 17 & 18, 2022. Jeff Wager, CEO of Spexis, will provide an overview of the company and its pipeline and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

The presentation is now available to conference registrants. For more information on the conference, visit the BioEquity website.

For further information please contact:

For Investors:

Hernan Levett
Chief Financial Officer
Spexis AG.
+41 61 567 16 00
IR@spexisbio.com

Raimund Gabriel
MC Services
spexis@mc-services.eu
Ph: +49 89 210 228 0

For Media:

Dr. Stephan Feldhaus
Feldhaus & Partner
+41 79 865 92 56
feldhaus@feldhaus-partner.ch

Dr. Brigitte Keller/Laurie Doyle
MC Services
spexis@mc-services.eu
Europe: +49 89 210 228 0
U.S.: +1 339 832 0752

About Spexis
Spexis is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland, focused on rare diseases and oncology. The current pipeline of the company is a combination of two legacy companies, Polyphor AG and EnBiotix, Inc. (Boston, MA, USA) which merged in December 2021. The combined company has been renamed to Spexis AG and is trading on the SIX Swiss Exchange under the symbol SIX:SPEX. For further information please visit: www.spexisbio.com.

Disclaimer
This press release contains forward-looking statements which are based on current assumptions and forecasts of Spexis management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Spexis' results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only as of the date of this communication. Spexis disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise.

End of Media Release

Language:	English
Company:	Spexis AG
	Hegenheimermattweg 125
	4123 Allschwil
	Switzerland
Phone:	+41 61 567 1600
Fax:	+41 61 567 1601
E-mail:	info@spexisbio.com
Internet:	www.spexisbio.com
ISIN:	CH0106213793
Valor:	SPEX
Listed:	SIX Swiss Exchange
EQS News ID:	1350291


End of News	EQS News Service

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END